ABBVIE Buy $ 2.1 billion Capstan, a new add-on at CAR-T to the pipeline

Abbvie agreed to obtain Capstan Therapeutics for $ 2.1 billion, adding a “high-risk and highly rewarding” clinical stage in the CAR-T candidate in the live body to its pipeline.

Capstan is developing a new type of T -cars Treatment that overcomes restrictions with current options. The treatments currently approved of this type work by upgrading the capacity of T -cells recovered by the patient to fight cancer cells, but this method has financial and expansion obstacles, along with the requirements of lymphatic chemotherapy and assimilation.

The leading Capstan assets, CPTX2309, is the Car-T treatment in the targeted sebaceous nanoparticles (LNP) anti-CD19 which can solve these problems. ABBVIE definitely sees the promise in the medicine, as it paid $ 2.1 billion in advance to control car therapy along with other before the clinical programs and the RNA RNA pulses used to create it.

CPTX2309, which is developed for the treatment of autoimmune diseases by cell B mediators, is already evaluated in the study of the first stage (NCT06917742) with healthy volunteers. Initial view of the data from Capstan revealed the drain of strong B cells-the goal of treatment is to achieve “immune reset” by re-installation of healthy B cells.

Investors shared the positive feelings in the acquisition, as the ABBVIE shares listed on the New York Stock Exchange closed by 1.7 % at $ 185.62 on June 30, the day the announcement was announced. Big Pharma’s market value is 327.9 billion dollars.

This is not the first relationship in Vivo Car-T that ABBVIE reinforced, in cooperation with UMOJA BIOPHARMA in January 2024. This ABBVIE partnership allows the development of candidates for Car-T cell treatment at site in oncology using VivoveCplatform.

“While CPTX2309 is still in early clinical development, we believe that the acquisition shows a strategic effort by ABBVIE to increase the enhancement of its immune concession through new mechanisms to adjust diseases,” said Matt Fibs, William Blair analyst, in a research note.

“Given the stage of evolution, this origin is clearly with a clinical danger, but given the potential in the living body, which does not require lymphocytes and has the possibility to increase the expansion of manufacturing, it provides a large bullish in the long run if it succeeds.”

Phips, who described the new assets of ABBVIE as “high -risk, highly deduced”, said the purchase process enhances the strong ABBVIE trading. Pharma’s large company is already ignorance The loss of the market by the Skyrizi (Risankizmab) and Rinvoq (Upadacitinib).